Drug Profile
Anti-CD3 monoclonal antibody 145-2C11
Alternative Names: 145-2C11; 145-2C11-IgG2a; 145-2C11-IgG3; 2C11; Anti-CD3 monoclonal antibody 2C11Latest Information Update: 15 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; PDL BioPharma; University of Cincinnati
- Developer Bristol-Myers Squibb; PDL BioPharma
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Transplant rejection